Search Results 851-860 of 19318 for Hemoglobin

  1. Choosing an air ambulance - Mayo Clinic

    Mayo Clinic's air ambulances carry a portable lab analyzer that measures arterial or venous blood gases, electrolytes, hemoglobin, lactate, and international ...

  2. Alisertib in Treating Young Patients with Recurrent or Refractory Solid Tumors or Leukemia - Mayo Clinic

    Hemoglobin ≥ 8.0 g/dL; Transfusions are permitted to meet both the platelet and hemoglobin criteria; patients must not be known to be refractory to red ...

  3. Neurology - Clinical trials - Mayo Clinic

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  4. Neurology - Clinical trials - Mayo Clinic

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  5. Neurology - Clinical trials - Mayo Clinic

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  6. Neurosurgery - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  7. Meet The Faculty - Hematopathology Fellowship (Minnesota) - Mayo Clinic College of Medicine & Science

    35,000 hemoglobin electrophoresis tests; 51,000 hematologic flow cytometry tests; 100,000 molecular hematology tests; 248,000 coagulation tests. Contact. Adam ...

  8. CC-4047 in Treating Patients With Myelofibrosis - Mayo Clinic

    Total hemoglobin < 10 g/dL OR transfusion dependent anemia (defined by a history of ≥ 2 units of red blood cell (RBC) transfusions within the past 28 days ...

  9. Mayo Clinic App Update Now Available On Android Platforms

    With enhanced navigation and functionality, the newest version of the app provides patients with an improved user experience managing and understanding their ...

  10. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis - Mayo Clinic

    Absolute decline in DLCO adjusted for hemoglobin ≥10% predicted within 1 year of follow-up. Radiological evidence of disease progression (one or more):.